Lyell Immunopharma (NASDAQ:LYEL) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of Lyell Immunopharma (NASDAQ:LYEL) from a hold rating to a sell rating in a research note released on Saturday,Wall Street Zen reports.

Several other equities analysts also recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lyell Immunopharma in a report on Thursday. Royal Bank Of Canada set a $34.00 price objective on shares of Lyell Immunopharma in a research report on Friday, August 14th. HC Wainwright reissued a “buy” rating on shares of Lyell Immunopharma in a research note on Friday, September 11th. Stifel Nicolaus assumed coverage on Lyell Immunopharma in a research report on Thursday, August 6th. They set a “buy” rating and a $36.00 target price for the company. Finally, Citigroup restated a “market outperform” rating on shares of Lyell Immunopharma in a research report on Friday, August 14th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.86.

Lyell Immunopharma Stock Up 8.4%

NASDAQ LYEL opened at $8.80 on Friday. The company has a fifty day moving average of $11.84 and a two-hundred day moving average of $14.95. The firm has a market capitalization of $215.60 million, a price-to-earnings ratio of -0.69 and a beta of -0.03. Lyell Immunopharma has a 52 week low of $7.20 and a 52 week high of $45.00.

Lyell Immunopharma (NASDAQ:LYEL) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($1.92) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.94) by $0.02. The business had revenue of $0.00 million for the quarter, compared to analysts’ expectations of $0.00 million. Lyell Immunopharma had a negative net margin of 920,285.25% and a negative return on equity of 91.62%. Equities research analysts anticipate that Lyell Immunopharma will post -7.16 EPS for the current year.

Institutional Investors Weigh In On Lyell Immunopharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LYEL. Walleye Capital LLC bought a new position in Lyell Immunopharma in the 1st quarter worth about $445,000. Bank of New York Mellon Corp purchased a new position in shares of Lyell Immunopharma during the second quarter worth approximately $347,000. Bank of America Corp DE increased its position in shares of Lyell Immunopharma by 314.2% during the first quarter. Bank of America Corp DE now owns 33,321 shares of the company’s stock worth $668,000 after acquiring an additional 25,276 shares during the period. Squarepoint Ops LLC raised its stake in shares of Lyell Immunopharma by 119.4% during the second quarter. Squarepoint Ops LLC now owns 42,322 shares of the company’s stock valued at $595,000 after acquiring an additional 23,028 shares in the last quarter. Finally, Dimensional Fund Advisors LP bought a new stake in shares of Lyell Immunopharma during the first quarter valued at approximately $959,000. Institutional investors own 66.05% of the company’s stock.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc is a clinical-stage biotechnology company focused on developing engineered T-cell therapies for cancer, with an emphasis on solid tumors. The company seeks to address limitations of existing cell therapies, including T-cell exhaustion, limited persistence and reduced activity within the tumor microenvironment.

Lyell uses cell-engineering and genomic technologies to develop investigational chimeric antigen receptor (CAR) T-cell and T-cell receptor (TCR) therapies.